title: 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.
abstract: The aims of this study were to establish the percentage of metastatic renal cell carcinoma (RCC) lesions detected by radioimmunoscintigraphy (RIS) with the chimeric monoclonal antibody 131I-cG250 versus positron emission tomography (PET) with 18F-labelled deoxyglucose ([18F]FDG), and to evaluate the use of these radionuclide imaging modalities compared with routinely used imaging techniques. Twenty patients with metastatic RCC disease were examined with [18F]FDG-PET and 131I-cG250 RIS within 1 week. Total body gamma camera images were obtained up to 120h after injection of 232MBq 131I-cG250. Total body PET scanning was performed 45-60 min after intravenous injection of 370MBq [18F]FDG. Nuclear medicine techniques were compared to routine imaging procedures. Routine imaging modalities revealed a total of 79 metastases. [18F]FDG-PET and 131I-cG250 RIS detected 33 previously unknown metastases, of which 32 were [18F]FDG positive and seven were 131I-cG250 positive. Of the 112 tumour lesions that were documented, [18F]FDG-PET detected 69% (77 out of 112), whereas 131I-cG250 RIS detected only 30% (34 out of 112). In conclusion, [18F]FDG-PET is superior to 131I-cG250 RIS in detecting metastases in patients with metastatic RCC, and therefore seems a promising tool for (re)staging patients with RCC. The usefulness of RIS with a diagnostic dose of 131I-cG250 seems to be restricted to selecting patients for radioimmunotherapy with 131I-cG250.
authors.affiliation: Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands. a.brouwers@nugen.azn.nl
authors.forename: A H
authors.initials: AH
authors.lastname: Brouwers
authors.forename: U
authors.initials: U
authors.lastname: Dorr
authors.forename: O
authors.initials: O
authors.lastname: Lang
authors.forename: O C
authors.initials: OC
authors.lastname: Boerman
authors.forename: W J G
authors.initials: WJ
authors.lastname: Oyen
authors.forename: M G
authors.initials: MG
authors.lastname: Steffens
authors.forename: E
authors.initials: E
authors.lastname: Oosterwijk
authors.forename: H G
authors.initials: HG
authors.lastname: Mergenthaler
authors.forename: H
authors.initials: H
authors.lastname: Bihl
authors.forename: F H M
authors.initials: FH
authors.lastname: Corstens
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000556:secondary*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011859:Radiography; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics
chemical_list: D000911:Antibodies, Monoclonal; C106533:G250 monoclonal antibody; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18